Villere ST Denis J & Co. LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Villere ST Denis J & Co. LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 62,442 shares of the company’s stock after purchasing an additional 1,556 shares during the period. IDEXX Laboratories accounts for about 2.3% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 23rd largest position. Villere ST Denis J & Co. LLC owned 0.08% of IDEXX Laboratories worth $25,816,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Adell Harriman & Carpenter Inc. purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $413,000. V Square Quantitative Management LLC increased its position in IDEXX Laboratories by 6.2% during the 4th quarter. V Square Quantitative Management LLC now owns 2,076 shares of the company’s stock valued at $858,000 after purchasing an additional 121 shares during the period. CFC Planning Co LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $487,000. Vontobel Holding Ltd. increased its position in IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after purchasing an additional 198,404 shares during the period. Finally, Asset Management One Co. Ltd. grew its position in shares of IDEXX Laboratories by 6.1% in the 4th quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company’s stock worth $21,927,000 after buying an additional 3,057 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $444.53 on Friday. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a 50 day simple moving average of $430.77 and a two-hundred day simple moving average of $453.31. The stock has a market cap of $36.40 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 3.47 and a beta of 1.37.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,330 shares of company stock worth $6,161,276. Company insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on IDXX shares. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Finally, Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.